vs

Side-by-side financial comparison of BlackSky Technology Inc. (BKSY) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

BlackSky Technology Inc. is the larger business by last-quarter revenue ($35.2M vs $19.6M, roughly 1.8× STANDARD BIOTOOLS INC.). BlackSky Technology Inc. runs the higher net margin — -2.5% vs -177.4%, a 174.9% gap on every dollar of revenue. On growth, BlackSky Technology Inc. posted the faster year-over-year revenue change (15.9% vs -11.5%). Over the past eight quarters, BlackSky Technology Inc.'s revenue compounded faster (20.5% CAGR vs -12.2%).

BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

BKSY vs LAB — Head-to-Head

Bigger by revenue
BKSY
BKSY
1.8× larger
BKSY
$35.2M
$19.6M
LAB
Growing faster (revenue YoY)
BKSY
BKSY
+27.4% gap
BKSY
15.9%
-11.5%
LAB
Higher net margin
BKSY
BKSY
174.9% more per $
BKSY
-2.5%
-177.4%
LAB
Faster 2-yr revenue CAGR
BKSY
BKSY
Annualised
BKSY
20.5%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BKSY
BKSY
LAB
LAB
Revenue
$35.2M
$19.6M
Net Profit
$-868.0K
$-34.7M
Gross Margin
48.5%
Operating Margin
-11.8%
-168.5%
Net Margin
-2.5%
-177.4%
Revenue YoY
15.9%
-11.5%
Net Profit YoY
95.5%
-28.8%
EPS (diluted)
$0.04
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKSY
BKSY
LAB
LAB
Q4 25
$35.2M
Q3 25
$19.6M
$19.6M
Q2 25
$22.2M
$21.8M
Q1 25
$29.5M
$40.8M
Q4 24
$30.4M
Q3 24
$22.5M
$22.1M
Q2 24
$24.9M
$22.5M
Q1 24
$24.2M
$45.5M
Net Profit
BKSY
BKSY
LAB
LAB
Q4 25
$-868.0K
Q3 25
$-15.3M
$-34.7M
Q2 25
$-41.2M
$-33.5M
Q1 25
$-12.8M
$-26.0M
Q4 24
$-19.4M
Q3 24
$-12.6M
$-26.9M
Q2 24
$-9.4M
$-45.7M
Q1 24
$-15.8M
$-32.2M
Gross Margin
BKSY
BKSY
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
BKSY
BKSY
LAB
LAB
Q4 25
-11.8%
Q3 25
-85.8%
-168.5%
Q2 25
-62.8%
-118.1%
Q1 25
-40.5%
-80.8%
Q4 24
-20.0%
Q3 24
-58.7%
-120.9%
Q2 24
-47.0%
-134.5%
Q1 24
-54.7%
-132.2%
Net Margin
BKSY
BKSY
LAB
LAB
Q4 25
-2.5%
Q3 25
-78.2%
-177.4%
Q2 25
-185.8%
-153.7%
Q1 25
-43.4%
-63.8%
Q4 24
-63.9%
Q3 24
-55.8%
-122.0%
Q2 24
-37.7%
-203.3%
Q1 24
-65.2%
-70.6%
EPS (diluted)
BKSY
BKSY
LAB
LAB
Q4 25
$0.04
Q3 25
$-0.44
$-0.09
Q2 25
$-1.27
$-0.09
Q1 25
$-0.42
$-0.07
Q4 24
$-0.61
Q3 24
$-0.66
$-0.07
Q2 24
$-0.52
$-0.12
Q1 24
$-0.88
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKSY
BKSY
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$124.5M
$129.4M
Total DebtLower is stronger
$201.1M
Stockholders' EquityBook value
$94.9M
$399.7M
Total Assets
$386.2M
$539.6M
Debt / EquityLower = less leverage
2.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKSY
BKSY
LAB
LAB
Q4 25
$124.5M
Q3 25
$146.5M
$129.4M
Q2 25
$93.8M
$158.6M
Q1 25
$75.8M
$150.9M
Q4 24
$52.5M
Q3 24
$63.2M
$210.6M
Q2 24
$41.2M
$269.8M
Q1 24
$35.4M
$287.1M
Total Debt
BKSY
BKSY
LAB
LAB
Q4 25
$201.1M
Q3 25
$195.1M
Q2 25
$122.5M
Q1 25
$115.3M
Q4 24
$107.7M
Q3 24
$98.8M
$55.2M
Q2 24
$108.6M
$55.1M
Q1 24
$85.0M
$55.0M
Stockholders' Equity
BKSY
BKSY
LAB
LAB
Q4 25
$94.9M
Q3 25
$91.1M
$399.7M
Q2 25
$86.6M
$424.5M
Q1 25
$88.8M
$454.6M
Q4 24
$94.0M
Q3 24
$110.3M
$489.3M
Q2 24
$76.5M
$510.3M
Q1 24
$81.7M
$577.3M
Total Assets
BKSY
BKSY
LAB
LAB
Q4 25
$386.2M
Q3 25
$380.9M
$539.6M
Q2 25
$310.8M
$557.0M
Q1 25
$284.9M
$579.6M
Q4 24
$254.1M
Q3 24
$245.5M
$681.5M
Q2 24
$224.3M
$708.7M
Q1 24
$210.1M
$777.7M
Debt / Equity
BKSY
BKSY
LAB
LAB
Q4 25
2.12×
Q3 25
2.14×
Q2 25
1.41×
Q1 25
1.30×
Q4 24
1.15×
Q3 24
0.90×
0.11×
Q2 24
1.42×
0.11×
Q1 24
1.04×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKSY
BKSY
LAB
LAB
Operating Cash FlowLast quarter
$-9.3M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKSY
BKSY
LAB
LAB
Q4 25
$-9.3M
Q3 25
$-39.0M
$-22.2M
Q2 25
$-7.3M
$-20.7M
Q1 25
$27.2M
$-30.3M
Q4 24
$-1.8M
Q3 24
$1.0M
$-27.9M
Q2 24
$-1.8M
$-39.0M
Q1 24
$-3.8M
$-62.5M
Free Cash Flow
BKSY
BKSY
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
BKSY
BKSY
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
BKSY
BKSY
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BKSY
BKSY

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons